<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="45380"><DrugName>NCP-004</DrugName><DrugSynonyms><Name><Value>NCP-004</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>peptide (diabetes, oral), Nobex</Value></Name></DrugSynonyms><CompanyOriginator id="21997">Nobex Corp</CompanyOriginator><CompaniesSecondary><Company id="21997">Nobex Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="45380" type="Drug"><TargetEntity id="371114" type="siDrug">NCP-004</TargetEntity></SourceEntity><SourceEntity id="21997" type="Company"><TargetEntity id="4296077484" type="organizationId">Nobex Corp</TargetEntity></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"></TargetEntity><TargetEntity id="D003920" type="MeSH"></TargetEntity><TargetEntity id="-203480060" type="omicsDisease"></TargetEntity><TargetEntity id="506" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="97">Diabetes mellitus</Indication></IndicationsSecondary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>A10</Code><Name>DRUGS USED IN DIABETES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-18T11:15:31.000Z</LastModificationDate><ChangeDateLast>2005-12-29T14:42:15.000Z</ChangeDateLast><AddedDate>2003-06-13T15:55:35.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="21997" linkType="Company"&gt;Nobex&lt;/ulink&gt; was investigating NCP-004, an orally administered peptide, for the potential treatment of diabetes [&lt;ulink linkID="493428" linkType="reference"&gt;493428&lt;/ulink&gt;]. Preclinical studies were ongoing in March 2004 [&lt;ulink linkID="527050" linkType="reference"&gt;527050&lt;/ulink&gt;]. As of October 2003, Nobex was seeking to outlicense worlwide codevelopment or exclusive rights to the formulation [&lt;ulink linkID="506729" linkType="reference"&gt;506729&lt;/ulink&gt;]; however, in December 2005, Nobex was reported to have filed for bankruptcy [&lt;ulink linkID="642186" linkType="Reference"&gt;642186&lt;/ulink&gt;], and it is presumed that it has ceased operations.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21997">Nobex Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="97">Diabetes mellitus</Indication><StatusDate>2005-12-06T00:00:00.000Z</StatusDate><Source id="642186" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21997">Nobex Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate>2003-06-13T00:00:00.000Z</StatusDate><Source id="493428" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>